OBJECTIVE: Previous studies have shown that in patients with ANCA-associated vasculitis (AAV), anti-plasminogen antibodies were associated with reduced renal function and the presence of fibrinoid necrosis and cellular crescents in renal histology. The purpose of the current study was to investigate whether anti-plasminogen antibodies are associated with the systemic disease activity of AAV. METHODS: One hundred and four Chinese patients with AAV were recruited. Anti-plasminogen antibodies were detected in sequential serum samples at initial onset and remission of the disease. Associations of anti-plasminogen antibodies with clinicopathological parameters were analysed. RESULTS: The prevalence of anti-plasminogen antibodies was significantly higher in AAV patients than in healthy controls (19/104 vs 0/50, χ(2) = 8.8, P = 0.003). The prevalence of anti-plasminogen antibodies was significantly higher in the active stage of AAV than in remission (19/104 vs 1/48, χ(2) = 7.5, P = 0.013). The level of anti-plasminogen antibodies (expressed as a percentage of the positive controls) correlated with the ESR (r = 0.207, P = 0.042), serum creatinine (r = 0.302, P = 0.002), d-dimer (r = 0.273, P = 0.009) and the percentage of glomeruli with crescents in renal specimens (r = 0.393, P = 0.004). The level of Birmingham vasculitis activity scores and the prevalence of arthralgia and gastrointestinal involvement in patients with anti-plasminogen antibodies were significantly higher than in patients without anti-plasminogen antibodies [22.5 (s.d. 5.63) vs. 19.4 (s.d. 4.66), P = 0.015; 63.2% vs. 25.8%, P = 0.002; 57.9% vs. 21.1%, P = 0.001, respectively]. CONCLUSION: Circulating anti-plasminogen antibodies were associated with systemic disease activity and renal disease activity of AAV.
OBJECTIVE: Previous studies have shown that in patients with ANCA-associated vasculitis (AAV), anti-plasminogen antibodies were associated with reduced renal function and the presence of fibrinoid necrosis and cellular crescents in renal histology. The purpose of the current study was to investigate whether anti-plasminogen antibodies are associated with the systemic disease activity of AAV. METHODS: One hundred and four Chinese patients with AAV were recruited. Anti-plasminogen antibodies were detected in sequential serum samples at initial onset and remission of the disease. Associations of anti-plasminogen antibodies with clinicopathological parameters were analysed. RESULTS: The prevalence of anti-plasminogen antibodies was significantly higher in AAVpatients than in healthy controls (19/104 vs 0/50, χ(2) = 8.8, P = 0.003). The prevalence of anti-plasminogen antibodies was significantly higher in the active stage of AAV than in remission (19/104 vs 1/48, χ(2) = 7.5, P = 0.013). The level of anti-plasminogen antibodies (expressed as a percentage of the positive controls) correlated with the ESR (r = 0.207, P = 0.042), serum creatinine (r = 0.302, P = 0.002), d-dimer (r = 0.273, P = 0.009) and the percentage of glomeruli with crescents in renal specimens (r = 0.393, P = 0.004). The level of Birmingham vasculitis activity scores and the prevalence of arthralgia and gastrointestinal involvement in patients with anti-plasminogen antibodies were significantly higher than in patients without anti-plasminogen antibodies [22.5 (s.d. 5.63) vs. 19.4 (s.d. 4.66), P = 0.015; 63.2% vs. 25.8%, P = 0.002; 57.9% vs. 21.1%, P = 0.001, respectively]. CONCLUSION: Circulating anti-plasminogen antibodies were associated with systemic disease activity and renal disease activity of AAV.
Authors: F David Carmona; Augusto Vaglio; Sarah L Mackie; José Hernández-Rodríguez; Paul A Monach; Santos Castañeda; Roser Solans; Inmaculada C Morado; Javier Narváez; Marc Ramentol-Sintas; Colin T Pease; Bhaskar Dasgupta; Richard Watts; Nader Khalidi; Carol A Langford; Steven Ytterberg; Luigi Boiardi; Lorenzo Beretta; Marcello Govoni; Giacomo Emmi; Francesco Bonatti; Marco A Cimmino; Torsten Witte; Thomas Neumann; Julia Holle; Verena Schönau; Laurent Sailler; Thomas Papo; Julien Haroche; Alfred Mahr; Luc Mouthon; Øyvind Molberg; Andreas P Diamantopoulos; Alexandre Voskuyl; Elisabeth Brouwer; Thomas Daikeler; Christoph T Berger; Eamonn S Molloy; Lorraine O'Neill; Daniel Blockmans; Benedicte A Lie; Paul Mclaren; Timothy J Vyse; Cisca Wijmenga; Yannick Allanore; Bobby P C Koeleman; Jennifer H Barrett; María C Cid; Carlo Salvarani; Peter A Merkel; Ann W Morgan; Miguel A González-Gay; Javier Martín Journal: Am J Hum Genet Date: 2016-12-29 Impact factor: 11.025
Authors: Arda Göçeroğlu; Elsa Grenmyr; Annelies E Berden; E Christiaan Hagen; Donna Bunch; Yngve Sommarin; Jan A Bruijn; Ingeborg M Bajema; Jörgen Wieslander Journal: PLoS One Date: 2018-11-12 Impact factor: 3.240
Authors: Carmen E Mendoza; Elizabeth J Brant; Matthew L McDermott; Anne Froment; Yichun Hu; Susan L Hogan; J Charles Jennette; Ronald J Falk; Patrick H Nachman; Vimal K Derebail; Donna O'Dell Bunch Journal: Kidney Int Rep Date: 2019-07-13